Head-to-head · The Match Score
Ondra Health vs Alan Meds
Both scored on the same six-factor Match Score. Ondra Health wins this matchup with a 88 to 86 edge.
Ondra Health
#3 · Grade B+
Value-seekers who still want a shot at brand-name meds and 50-state availability.
Visit Ondra HealthAlan Meds
#7 · Grade B+
Budget shoppers who want an oral/sublingual route without giving up nationwide access.
Visit Alan MedsFactor by factor
The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.
Price, coverage & formulary
| Detail | Ondra Health | Alan Meds |
|---|---|---|
| Semaglutide | $93/mo | $99/mo |
| Tirzepatide | $166/mo | $145/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injectable only | Yes |
| Match Score | 88 · B+ | 86 · B+ |
Ondra Health edges out Alan Meds, 88 to 86 on the default Match Score. Near rock-bottom pricing on both molecules plus some brand access — a rare budget-and-breadth combo, nationwide.
Alan Meds is still a fair pick if its strengths line up with yours — best for: Budget shoppers who want an oral/sublingual route without giving up nationwide access.
Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.
Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.
More head-to-heads
- Ondra Health vs CoreAge Rx
- Ondra Health vs Eden
- Ondra Health vs Vaylen
- Ondra Health vs ShedRx
- Ondra Health vs Curex
- Ondra Health vs Effecty
Or browse alternatives to Ondra Health and all comparisons.
Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.